ITM

Furthermore, ITM is developing a proprietary portfolio and growing Precision Oncology Pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, prostate cancer, folate receptor α positive tumors like ovarian cancer or NSCL adenocarcinoma, as well as osteosarcoma and bone metastases. ITM's lead candidate n.c.a. 177 Lu-edotreotide, a Targeted Radionuclide Therapy to specifically target neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs), is currently undergoing two international pivotal phase III clinical trials, COMPETE and COMPOSE... ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment... ITM AG is dedicated to the development, production and global..

Also known as: ITM Isotope Technologies Munich SE, ITM Radiopharma

Registration numbers: HRB 269592 (W)

VAT numbers: DE 813228901

Primary location: Munich Germany